Upload
others
View
2
Download
0
Embed Size (px)
Citation preview
University of TurinItaly
NON INVASIVE FOLLICULAR TUMORS WITH PAPILLARY-LIKE NUCLEI (NIFT-P)
Veenendaal, April 13, 2018
Mauro PapottiM. Volante F. MalettaJ. Metovic
PTC-likeFT+NI+
WHO CLASSIFICATION OF ENDOCRINE TUMORS
June 2017
WHO 2017
Hobnail var.
Follicularpatterned
tumors
WD THYROID TUMORSCURRENT STATUS
FA FTC
PA PTC
WD THYROID TUMORS….DETAILED TYPING….
FA
PA
WI FTCMI FTC
PTCCl., FV,..
EFVPTC non inv
IFVPTCmicroCa cl.V
Lloyd RV et al: Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. AJSP 28:1336-1340, 2004.
Split diagnosis occurred up to 40%!
Using 87 cases of FVPTC from Mayo Clinic
modified from Kakudo 2015
ENCAPSULATED FOLLICULAR TUMORS
Conclusion on 83 tumors
ENCAPSULATED FOLLICULAR TUMORS WITH PTC NUCLEI (towards “NIFT-P”)
Background
Diagnostic PTC type nuclear features in encapsulated tumors?
1. Nuclear enlargement (oval shape & elongation) 2. Overlapping nuclei. 3. Irregularity of nuclear contours (grooves) 4. Cytoplasmic nuclear inclusion (DD vacuoles:
>50% nuclear area with distinct border and cytoplasmic staining color)
5. Ground glass nuclei, clear or powdery nuclei
The WHO textbook stated that in tumors without complex papillary structures, the diagnosis of PTC relies on these nuclear features, which should be present in a significant proportion of the neoplasm If they are minor/focal, it should be classifed as uncertain category (WDT-UB).
Liu Z Cancer Sci 2011; Kakudo K Endocr J 2011 – modified from Kakudo 2015
FTC
no
FA
PTC-N
yes equivocal no
EnFV-PTC WDT-UB
Encapsulated Follicular Cell Tumours
Diffuse/
Predominate
Minor/
Focalyes
Both are called PTC
in most Western countries
Capsular invasion
equivocal
FT-UMP
modified from Kakudo 2015Liu Z et al. Cancer Sci, 2011
Kakudo K et al. Endocr J, 2011
“NIFT-P” Background & study design
PTC includes follicular var. (no papillae), -which includes encapsulated forms, -which include 100% non invasive forms,-which follow an indolent course.
Are these “cancers” (ie malignant)?Are these papillary adenomas (but no papillae)?Are these follicular adenomas (but PTC nuclei)?Are these something else?
-24 pathologists from 3 continents-250 cases individually reviewed & scored -10 TC to discuss diagnostic criteria -decision on the name for this new entity
Score 0 1 432
Nuclear Features Score for “EFVPTC”
Nik
iforov
20
15
(p
erso
nal
com
mu
nic
ati
on
)
Score 5 6 987
Nuclear features:
1. Size and Shape
Enlargement
Elongation
Overlapping
2. Membrane Irregularities
Irregular contours
Grooves
Pseudoinclusions
3. Chromatin Characteristics
Chromatin clearing
Margination of chroma-
tin to membrane
Glassy nuclei
Nuclear score: Sum of three nuclear features (each 0 or 1)So total score will vary between 0 and 3
Absent/insufficiently expressed (0) Present/Sufficient (1)
(May 18,
2015)
Slight changes not sufficient to call “yes” !
modified from Nikiforov 2015
New nuclear feature score for “EFVPTC”
My understanding after>200 case review, several exercises, 8 TC, 2 day meeting
Example of NIFTP
WD THYROID TUMORS
FA
PA
WI FTCMI FTC
PTCCl, FV, ..microCa cl.V
IFVPTC
EFVPTC non inv
Non invasive/encapsulatedfollicular tumors including PTC
WD THYROID TUMORSWHERE DOES NI EFVPTC STAND?
FA
PA
WI FTCMI FTC
PTCCl, FV, ..microCa cl.V
IFVPTC
EFVPTC non inv
EFVPTC non inv
EFVPTC non inv
EFVPTC non inv
?
?
??
WD THYROID TUMORSREVISION OF EFVPTC non invasive
FA
PA
WI FTCMI FTC
PTCCl, FV, ..microCa cl.V
IFVPTC
NO papillae
WHY THE NAME NIFTP?
Highly criticized terminology !!
But you should first be aware of the proposed alternatives…..!!!
JAMA ONCOLOGY Apr 14 2016
MOLECULAR PROFILE OF NIFTP
RAS gene mutations are more common than BRAF in follicular variant PTC
FVPTC MOLECULAR PROFILE
BRAFRAS
InfiltrativeEncapsulated
FVPTC MOLECULAR PROFILE
NIFTP MOLECULAR PROFILE
Seethala AJSP 2017,41,446
TERT promoter mutations usually do notoccur in NIFTP. One true case is reported, with no high grade features. Unexplained
Jiang XS. Cancer 2016, 124,893
ETV-NTRK3 rearrangements usually do notoccur in NIFTP. Reported cases exist, butthe capsule was not entirely examined, and rare papillae or infiltrative growth may beidentified
RAS mutations in EFVPTC / NIFTP vs BRAF or RET/PTC in infiltrative FVPTC
Kim TH. Histopathology 2018, 72,648
PTC nuclei & papillae vs follicles
NIFTP VALIDATION PAPERS
Additional features: -multifocal tumors-bilateral tumors-microcarcinomas-large NIFTP
Large NIFTPs appear to have an extremely lowrisk of recurrence (zero in this cohort), even afterconservative tx, without RAI. Surgical treatment alone (lobectomy) appears to be adequate.
NIFTP PAPERS
2017
2017
NIFTP: ATA GUIDELINES(...) It is recommended that the histopathologic nomenclature for EFVPTC without invasion be reclassified as a NIFTP, given the excellent prognosis of thisneoplastic variant. (...)
It is also noted that prospective studies are needed to validate the observed patient outcomes(and test performance in predicting thyroid canceroutcomes), as well as implications on patients' psychosocial health and economics.
2017;27:481-483. American Thyroid Association Guidelines on the Management of ThyroidNodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma WithoutInvasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features.
NIFTP: summary of diagnostic cluesas of 2018
-PTC like nuclear features (score 0-3)-Only scores 2-3 indicate NIFTP (vs FA)-Extensive capsular sampling (possibly all)-NO papillae (originally <1%)-NO psammoma bodies (linked to papillae)-NO infiltrative growth into the capsule-NO upper limit of NIFTP size (ok even >4)-Lower cutoff at 1 cm; sub-cm cases exist
-NO BRAF mutations-Reported NIFTP with mets are not NIFTP!
Hung & Barletta. A user’s guide to NIFTP. Histopathology 2018
Seethala et al. NIFTP: a review for pathologists. Mod Pathol 2018
NIFTP: summary of diagnostic cluesas of 2018
Nuclear features:
1. Size and Shape
Enlargement
Elongation
Overlapping
2. Membrane Irregularities
Irregular contours
Grooves
Pseudoinclusions
3. Chromatin Characteristics
Chromatin clearing
Margination of chroma-
tin to membrane
Glassy nuclei
Nuclear score: Sum of three nuclear features (each 0 or 1)So total score will vary between 0 and 3
Absent/insufficiently expressed (0) Present/Sufficient (1)
Slight changes not sufficient to call “yes” !
modified from Nikiforov 2015
NIFTP & FNA CYTOLOGY
PAPILLARY ARCHITECTURE
+/-
PTC
FTC
NUCLEAR IRREGULARITIES
VASCULAR INVASION
and / or
CAPSULAR PENETRATION
FNA YES
FNA NO
FNA NO
FNA YES
PTC type Nuclear Features
FNA DIAGNOSIS OF NIFTP?
-96 cases from 6 University hospitals (Torino, Bologna, Pisa)-Revision of anonymized surgical casesoriginally diagnosed as EFVPTC, WDT-UMP or FA with occasional clear nuclei, and having the corresponding FNA materialavailable-Criteria for NIFTP
-Exclusion criteria: no encapsulation, VI, capsular penetration, papillae in >1%, multifocality, Hurthle cellchanges (ie oncocytic variant PTC)
FNA DIAGNOSIS OF NIFTP?
Correspondinghistologicalfeatures
96 FNA+surgery from 6 Univ. hospitals
FNA DIAGNOSIS OF NIFTP?
SAME CRITERIA:1. Size and Shape
• Enlargement
• Elongation
• Overlapping
2. Membrane Irregularities
• Irregular contours
• Grooves
• Pseudoinclusions
3. Chromatin Characteristics
• Chromatin clearing
• Margination to membrane
• Glassy nuclei
Cell blocks
*Mostly Bethesda category IV or V (Tir 3b or 4)*In a well demarcated nodule (at US) with follicular growth & more or less evident PTC nuclei, consider NIFTP & at least avoid the category «malignant» (Bethesda VI or Tir 5)
NIFTP IN FNAB CYTOLOGY
+ Aug 2, 2015
Giemsa HE PAP
NIFTP IN FNAB CYTOLOGY2017
III 20%, IV 42%, V 25%, VI 4%
Strickland KC, Vivero M, …, Barletta J, Krane JF. Pre-operative CytologicDiagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP): A Prospective Analysis. Thyroid 2016 Jul 25.
Excluding 7 indeterminate cases, 89% (8/9) of nodules classified as NIFTP/FVPTC on FNA demonstrated follicular-patterned lesions on histology (5 NIFTP, 1 invasive FVPTC, 2 follicular adenomas). Cytopathologistsprospectively identified cPTC in 95% (38/40) of cases.
NIFTP IN FNAB CYTOLOGY
Ibrahim AA, Wu HH. FNA Cytology of Noninvasive Follicular Variant of Papillary Thyroid Carcinoma Is Cytomorphologically Distinct From the Invasive Counterpart. Am J Clin Pathol 2016 Sep;146:373-7.
Matched FNA & surgical samples: 23 noninvasive FVPTC and 27 cases infiltrative FVPTC (n = 16) or encapsulated FVPTC with invasion (n = 11).
FNA diagnoses: NIFTP: 4 benign lesions, 14 FLUS, 4 FN, 1 suspicious, no PTC.
Invasive FVPTC group: no benign, 4 FLUS, 3 FNs, 12 suspicious, 8 PTC.
CONCLUSIONS: There is a distinction in the cytologic diagnosis between noninvasive and invasive FVPTC. The invasive subtype was diagnosed by FNA as suspicious for PTC or PTC in nearly 75% of cases, while only one (4%) case for the noninvasive subtype was diagnosed as suspicious for PTC (P < .05).
NIFTP IN FNAB CYTOLOGYHahn SY et al. Preoperative differentiation between noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) and non-NIFTP. Clin Endocrinol(Oxf) 2016 Oct 19. 208 resected FVPTC: 34 NIFTP (16·3%) and 174 non-NIFTP (83·7%).
Clinical factors, the biopsy techniques and ultrasonography (US) imaging characteristics were compared between NIFTP and non-NIFTP groups.
The most common biopsy diagnosis of NIFTP was Bethesda category V
(28·6%) in the US-FNA group and category IV (45·5%) in the US-CNB group.
By US, NIFTP had lower suspicion of malignancy than non-NIFTP (p:0.024).
NIFTP lacks malignant US features and is better triaged using US-CNB than
using US-FNA to facilitate the surgical management.
Jeon MJ et al. Impact of Reclassification on Thyroid Nodules with Architectural Atypia: From Non-Invasive Encapsulated FVPTC to NIFTP. PLoS One 2016;11:e0167756
-Impact of reclassification from EFVPTC to NIFTP [Resected 384/1301 nodules, 30%].
-Reviewed 1301 thyroid nodules with architectural atypia in core needle biopsy (CNB)
-Classified into atypia of undetermined significance with architectural atypia (AUS-A, 984, 76%) or follicular neoplasm/suspicious for a follicular neoplasm (FN/SFN, 317, 24%).
-The malignancy rate was estimated: 7-35% in AUS-A nodules and 28-49% in FN/SFN nodules. After reclassification, the malignancy rate was 5-24% & 23-39% respectively.
CONCLUSIONS: After reclassification of non-invasive EFVPTCs to NIFTPs, the
malignancy rate of thyroid nodules with architectural atypia in CNB specimens was
decreased. However, there were no preoperative factors differentiating other
malignancies from NIFTPs.
NIFTP IN FNAB CYTOLOGYH
C
J
C
NIFTP IN FNAB CYTOLOGY: score 0-1
NIFTP IN FNAB CYTOLOGY: score 2
score 2.5 ?
NIFTP IN FNAB CYTOLOGY: score 3
I) Nondiagnostic //
II) Benign <1%
III) Follicular lesion / 5-10%
atypia of undetermined significance
IV) Follicular neoplasm / 20-30%
suspicious for follicular neoplasm
V) Suspicious for malignancy 50-75%
VI) Malignant 100%
Risk of malignancyBethesda 2007 and 2010
Evaluation of risk of malignancychanges in the Bethesda classification
Risk of malignancy changes in the Bethesda classification
-1,886 thyroid FNAs with surgical follow-up -EFVPTC were 27% (94/343) of the malignant cases.-Malignancy ratios in nondiagnostic, benign, atypia/FLUS, FN, suspicious for malignancy, and malignant categories were 13, 7, 45, 30, 72, 98%, respectively. -If EFVPTC was not regarded as malignant, malignancy ratios would decrease to 6.5, 6, 30, 10, 48, 87% for each category.-The most significant decrease occurred in follicular neoplasm category (66% relative decrease)
Canberk et al. New concept of the encapsulated FVPTC and its impact on the Bethesda system for reporting thyroid cytopathology: a single-institute experience. Acta Cytol 2016;60:198-204.
-Tested by Nanostring 798 miRNA expression profiles to distinguish between NIFTPs (#19) vs FA (#18) and infiltrative FVPTC (#18).
-miR-146-5p, miR-221-5p, miR-222-3p, miR-30e-3p, and miR-152-3p could significantly discriminate between benign and malignant lesions (P<0.001). Infiltrative FVPTC have high levels of miR-146-5p, miR-199a-5p, miR-199b-5p, miR-1285-5p, miR-1915-3p, miR-4516, and low miR-148b-3p.
-miR-152-3p, miR-185-5p and miR-574-3p were significantly downregulated in NIFTPs compared with FA, whereas miR-10a-5p and miR-320e can discriminate between NIFTPs and infiltrative FVPTC.
-A panel of these markers could have high diagnostic potential & could be applied to presurgicalindeterminate lesions by FNA.
MOLECULAR DATA OF NIFTP IN FNA
Borrelli N,…, Basolo F. miRNA expression profiling of NIFTP compared with FA and infiltrative FVPTC. Mod Pathol 2017;30:39-51
MOLECULAR TESTS for FNA CYTOLOGY
Encapsulated non invasive FT
AFIP 2014
WHO 2017
0.5-8%
0.6-7.6%
NIFT-P “FORMULA”
Mauro Papotti, Univ Turin
++NI PTC-likeFT = NIFT-P
Growth +Architecture+Cytology=
no papillae
no invasion
Thank you!!
Mauriziano hospital, dr Gianni DeRosa
University of Turin
Medical School
San Luigi hospital
Molinette hospital